Tylenol, Theraflu, NyQuil, and DayQuil
Allegations: Falsely marketing that phenylephrine products treat nasal congestion
Chamberlain et al. v. Johnson & Johnson Consumer Inc., RB Health LLC, GlaxoSmithKline Consumer Healthcare Holdings (US), LLC
23-cv-4435, E.D. Penn.
(Nov. 2023)
Travis et al. v. Procter & Gamble Co., Kenvue, Inc., McNeil Consumer Healthcare, Reckitt & Benckiser LLC and GlaxoSmithKline, LLC
23-cv-607, S.D. Ohio
(Sept. 2023)
Advil, Tylenol, DayQuil, NyQuil, TheraFlu, Sudafed, and other cold and flu medicines
Falsely marketing that medicines are decongestants when the active ingredient (phenylephrine) is not an effective decongestant
Pending
Allegations: Falsely marketing that phenylephrine products treat nasal congestion
Allegations: Falsely marketing that phenylephrine products treat nasal congestion
Allegations: Falsely marketing that medicines treat nasal congestion
Allegations: Falsely marketing the products treat nasal congestion
Allegations: Falsely marketing that phenylephrine products treat congestion and other cold and flu symptoms
Allegations: Falsely marketing that medicines treat nasal congestion
Allegations: Falsely marketing that medicines treat nasal congestion
Allegations: Misleadingly marketing drink mixes using the phrase “Natural fruit flavor” and images of raspberries when they contain artificial flavoring ingredients
Allegations: Misleadingly marketing products as if they treat symptoms of coughs and colds
Allegations: False natural claims
Allegations: False natural claims
When did the soap game get so dirty?
Green marketing claims you should think twice about.
TINA.org Joins with AARP in Objecting to Move Free Class-Action Settlement MADISON, Conn., March 12, 2015 — More than 46 million people suffer from arthritis, many of them elderly, and…
Consumers report adverse reactions.
Self-regulatory body calls supporting evidence behind superiority claims “materially flawed.”